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ABSTRACT 
Background & Aims: Cholangiocarcinoma (CCA) is a cancer of the hepatic bile ducts that is 
rarely resectable and associated with poor prognosis. New therapeutic strategies are urgently 
required. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is known to signal 
via its receptor fibroblast growth factor-inducible 14 (Fn14) and induce cholangiocyte and 
myofibroblast proliferation in liver injury. Its role in CCA remains undefined.  
Methods: The expression of TWEAK ligand and Fn14 receptor was assessed 
immunohistochemically and by bulk RNA and single cell transcriptomics of human liver tissue. 
Spatiotemporal dynamics of pathway regulation were comprehensively analysed in rat and 
mouse thioacetamide (TAA)-mediated CCA. Flow cytometry, qPCR and proteomic analyses 
of CCA cell lines and conditioned medium experiments with primary macrophages were 
performed to evaluate TWEAK/Fn14 downstream functions. In vivo pathway manipulation 
was assessed via TWEAK overexpression in NICD/AKT-induced CCA or genetic Fn14 
knockout during TAA-mediated carcinogenesis.  
Results: Our data reveal TWEAK and Fn14 overexpression in multiple human CCA cohorts, 
and Fn14 upregulation in early TAA-induced carcinogenesis. TWEAK regulated the secretion 
of factors from CC-SW-1 and SNU-1079 CCA cells, inducing polarisation of pro-
inflammatory CD206+ macrophages. Pharmacological blocking of the TWEAK downstream 
target chemokine monocyte chemoattractant protein 1 (MCP-1) significantly reduced CCA 
xenograft growth, while TWEAK overexpression drove cancer-associated fibroblast 
proliferation and collagen deposition in the tumour niche. Genetic Fn14 ablation significantly 
reduced inflammatory, fibrogenic and ductular responses during carcinogenic TAA-mediated 
injury. 
Conclusion: These novel data provide evidence for the action of TWEAK/Fn14 on 
macrophage recruitment and phenotype, and cancer-associated fibroblast proliferation in CCA. 
Targeting TWEAK/Fn14 and its downstream signals may provide a means to inhibit CCA 
niche development and tumour growth. 
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Lay summary: Cholangiocarcinoma is an aggressive, chemotherapy-resistant liver cancer. 
Interactions between tumour cells and cells that form a supportive environment for the tumour 
to grow are a source of this aggressiveness and resistance to chemotherapy. Herein, we describe 
interactions between tumour cells and their supportive environment via a chemical messenger, 
TWEAK and its receptor Fn14. TWEAK/Fn14 alters the recruitment and type of immune cells 
in tumours, increases the growth of cancer-associated fibroblasts in the tumour environment, 
and is a potential target to reduce tumour formation. 
 
 
Graphical abstract: 
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INTRODUCTION 
Cholangiocarcinomas (CCA) are aggressive hepatic malignancies, typically adenocarcinomas 
morphologically resembling hepatobiliary epithelium, expressing cytokeratins (CK) CK7 and 
CK19 but not CK20 or Hep-Par1[1-3]. CCA occurs at all regions of the biliary tree and is 
classified according to anatomical location; intrahepatic (iCCA; 20%), peri-hilar (pCCA; 50-
60%) or distal (dCCA; 20-30%)[3, 4]. CCA remains clinically challenging due to late-stage 
presentation, chemotherapy resistance, and high post-surgery recurrence [3]. Consequently, 5-
year survival rates remain below 25% [5].  
 
CCA develops a characteristic thick, fibrous stroma composed of α-smooth muscle actin 
(αSMA)-expressing cancer-associated fibroblasts (CAFs), tumour-associated macrophages 
(TAMs), neutrophils and vascular endothelial cells [3]. Stromal cells interact with neoplastic 
ducts via several signals including Wingless-related integration site (Wnt) [6, 7], Notch [8, 9], 
Platelet-Derived Growth Factor [10, 11], Stromal-Derived Factor-1/C-X-C chemokine receptor 
type-4 [12, 13] and numerous cytokines, to support growth, evasion of apoptosis and promote 
metastatic progression via modulation of protein kinase-B (AKT) and extracellular signal-
regulated kinase (ERK) pathways [13-15]. CD14+/CD16+ peripheral blood monocytes are 
elevated in patients [16], and are recruited to tumour areas, where they differentiate into TAMs 
[17, 18]. TAM infiltration is correlated with tumour recurrence, metastasis and decreased 
survival [17, 19]. Fluorescently-tagged bone marrow-derived macrophages comprise the 
majority of CD206+ TAMs in a rat CCA model, and secrete tumour-feeding Wnt ligands [7]. 
Ablating TAMs significantly reduces tumour formation, highlighting the importance of 
macrophage-derived factors in maintaining CCA [7].  
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The TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 
(Fn14) pathway acts via TWEAK ligand binding to its cognate receptor, Fn14, activating NF-
κB/MAPK/PI3K/AKT downstream signalling [20] to regulate proliferation, survival, 
inflammation and angiogenesis. TWEAK is ubiquitously expressed in adult liver by 
macrophages, with signalling modulated by dynamic regulation of Fn14 during injury and 
repair [20, 21]. TWEAK initiates non-hepatocyte-mediated regeneration via canonical NF-κB-
induced cholangiocyte proliferation [21, 22] and drives fibrosis-mediating hepatic stellate cell 
proliferation within the injury niche [23]. TWEAK-expressing macrophages were recently 
identified as key drivers of fibrosis, controlling Fn14+ HSC proliferation in human cirrhotic 
liver [24]. TWEAK also stimulates proliferation of hepatocellular carcinoma cell lines [25], 
potentiating a role in liver cancer growth.  
 
We hypothesised that the principal role of TWEAK during chronic liver disease and CCA 
development may be two-fold: (i) to act as a canonical NF-kB pathway-driven mitogen 
controlling neoplastic duct and CAF proliferation and (ii) to induce NF-kB-driven chemotaxis-
associated signalling during the establishment, maintenance and progression of CCA. We 
demonstrate that the TWEAK/Fn14 pathway is increasingly expressed during multi-species 
CCA development, regulating proliferation, migration and polarisation of cells, including 
macrophages and CAFs in the tumour niche, establishing TWEAK/Fn14 signalling as a novel, 
therapeutically targetable driver of CCA development. 
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MATERIALS AND METHODS 
Study approval 
Animal experiments were approved by the University of Edinburgh animal ethics committee 
with U.K. Home Office approval (70/7847, 70/8150, P231C5F81) or performed according to 
the Australian code for the care and use of animals for scientific purposes at Curtin University 
(AEC_2014_29). Retrospectively collected specimens were obtained from the National Health 
Service Lothian Scottish Academic Health Sciences Collaboration BioResource and healthy 
liver from the Edinburgh Medical Research Council Sudden Death Tissue Bank (10/H0716/3). 
Human blood was collected under ethical approval from the University of Edinburgh (15-HV-
013). All human tissue samples were collected with informed consent. 
 
All other methods can be found in the Supplementary Materials and Methods or the 
Supplementary CTAT Table.  
 
RESULTS 
1. TWEAK and Fn14 upregulation in multi-species CCA  
We assessed Fn14 expression in archival CCA samples and interrogated publicly available 
mRNA expression data to ascertain whether the TWEAK/Fn14 pathway was overexpressed in 
CCA, and to define cell type interactions of ligand and receptor. In a cohort of pathologically 
confirmed human iCCA cases, Fn14 was highly expressed by malignant epithelia, localising at 
the surface of these cells. Lower expression was observed in bile ducts in surrounding liver 
(SL) areas of non-tumour liver tissue, with diffuse staining in hepatocytes. Fn14 was 
identifiable in endothelial cells within portal triads. Positive stromal cell staining consistent 
with CAFs was observed in a subset of samples (Figure 1A). Quantification confirmed 
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increased Fn14 expression in CCA versus non-CCA areas (Figure 1B), corroborated by 
interrogation of publicly available transcriptomic data. In a scRNA-seq dataset (GSE125449; 
[26]), Fn14 was mainly expressed by malignant cells, and subsets of CAFs and hepatic 
progenitor cells (HPCs). TWEAK expression was mainly observed in a subset of TAMs in 
iCCA (Figure 1C). Fn14 and TWEAK were significantly upregulated in tumour tissue versus 
non-involved liver in the TCGA-Chol cohort (Supplementary Figure 1A) and in a microarray 
dataset (GSE26566; [27]: Supplementary Figure 1B).  
 
We then assessed the distribution of Fn14 in PanCK+ tumour epithelia and αSMA+ CAFs in an 
iCCA tissue microarray, where 42.50% of tumour cells (n=83 samples containing PanCK+ 
cells) and 62.64% of CAFs (n=79 samples containing αSMA+ CAFs ) expressed Fn14 (Figure 
1D). We observed a greater proportion of Fn14+ CCA cells in well-differentiated (grade 1) 
versus poorly differentiated (grade 3) iCCAs, but no association between tumour grade and the 
proportion of Fn14+ CAFs (Figure 1D). No association was observed between TNM stage and 
proportion of Fn14+ cells (Supplementary Figure 1C), supported by assessment of TCGA-Chol 
samples with respect to TNM stage (Supplementary Figure 1D).  
 
Since archival human tissue samples represent end-stage CCA, we performed time course 
analyses to observe the temporal relationship of TWEAK/Fn14 expression to CCA 
development using rodent models of thioacetamide (TAA)-mediated injury (Figure 2A). 
Histological examination of Fn14-stained serial sections by a specialist liver histopathologist 
found that Fn14 was readily identifiable in dysplastic biliary lesions and early CCA (10-18 
weeks; Supplementary Figure 2A). Similar to human data, Fn14 was observed at the cell 
surface of biliary lesions/CCA cells, some endothelial cells and transiently in damaged 
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hepatocytes (Supplementary figure 2). Fn14 was transiently upregulated in PanCK+ ducts and 
surrounding damaged hepatocytes at 10 weeks (Figure 2B and Supplementary Figure 2A), 
which reduced as injury progressed and more PanCK+ cells were detected. As malignancy 
developed, subsets of PanCK+ cells expressing Fn14 emerged. Fn14 expression continued in 
CCA epithelia but not in non-malignant ducts (Figure 2B and Supplementary Figure 2B). 
Biphasic Fn14 expression was mirrored transcriptionally, peaking at 10 and 20 weeks of TAA 
treatment. TWEAK mRNA increased steadily over the time course (Figure 2C). Transcripts of 
the pro-fibrotic markers collagen type 1α1, transforming growth factor-β1, tissue inhibitors of 
metalloproteinases (Timp1, Timp2) and matrix metalloproteinases (MMP2, MMP9) exhibited 
a comparable biphasic expression (Supplementary Figure 3).  
 
We assessed expression of TWEAK ligand and Fn14 receptor in a transgenic model of CCA 
induction, where CCA develops during TAA treatment in livers with CK19-inducible Cre-
recombinase driven p53-deficiency, but not in mice with at least one functional p53 allele 
(Figure 2D; [28]). TAA-treated K19-p53f/f mice significantly increased TWEAK and Fn14 
mRNA and protein levels during CCA formation, compared to mice without CCA (K19-
p53flox/WT and K19-p53WT/WT; p53WT/het), measured by qPCR (Figure 2E) and Fn14 by western 
blotting (Figure 2F).  
These data associate the transition of normal duct epithelium to iCCA with the upregulation of 
TWEAK/Fn14 pathway and suggest a potential function during development and maintenance 
in multi-species CCA.  
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2. TWEAK/Fn14 modulates NF-κB-regulated cytokine/chemokine secretion in CCA cells  
To assess function of TWEAK/Fn14 in CCA epithelia, we studied the effects of recombinant 
human TWEAK (rhTWEAK) treatment in four well-characterised iCCA cell lines, all 
expressing cell surface Fn14 (Supplementary Figure 4A). TWEAK stimulation uniformly 
induced canonical p65 NF-κB phosphorylation, processing of non-canonical NF-κB p100 to 
p52 in CC-SW-1 and SNU-1079 cells (Figure 3A), and stimulated nuclear translocation of p65 
in CCA cells (Figure 3B). Despite consistent rhTWEAK-mediated NF-κB activation in all cell 
lines, only SNU-1079 and HuH-28 cells displayed a mitogenic response to rhTWEAK (Figure 
3C).  
 
NF-κB regulates a variety of pro-inflammatory and pro-fibrogenic responses in liver disease 
[29]. Since a key element of CCA development is the formation of a stimulatory, pro-
tumorigenic niche, we investigated TWEAK-induced gene expression changes in CCA cells. 
We observed TWEAK-inducible mRNA expression of MCP-1 (3/4 cell lines), CX3CL1 (3/4 
cell lines), IL-6 (1/4 cell lines), IL-8 (3/4 cell lines), M-CSF (3/4 cell lines) and GM-CSF (2/4 
cell lines) (Figure 3D). To determine pathway specificity, we assessed TWEAK-inducible gene 
expression in the presence and absence of inhibitors of canonical or non-canonical NF-κB 
signalling in CCA versus HCC cells. Generally, TWEAK-induced gene expression was 
subdued by canonical NF-κB inhibition in CCA lines. IL-6 was inhibited by both inhibitors, 
whereas CX3CL1 and M-CSF were not affected by either inhibitor in CC-SW-1 cells. Likewise, 
CX3CL1 expression was not affected by either inhibitor in HuH-28 cells. TWEAK-induced gene 
expression was not observed in HepG2 HCC cells (Supplementary Figure 4B). 
We observed significantly increased TWEAK-induced secretion of MCP-1 (all cell lines), IL-
8 (2/4 cell lines) and GM-CSF (all cell lines) into the cell culture medium (Figure 3E). We also 
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characterised proteins present in conditioned medium from PBS- or TWEAK-treated cells by 
mass spectrometry. Secreted proteins that were present in both PBS- and TWEAK-treated cell 
line conditioned medium, or in TWEAK-treated conditioned medium alone, were assessed for 
protein-protein interactions and ‘biological process’ gene ontology (GO) enrichment 
(Supplementary Figures 5-8). Several GO terms associated with pro-tumour microenvironment 
development were enriched in TWEAK-conditioned medium, including extracellular matrix 
(ECM) development (ECM organisation), blood vessel development (angiogenesis, blood 
vessel remodelling/development) and immune modulation (regulation of 
leukocyte/macrophage chemotaxis, immune system process, immune response) in a cell line-
specific manner.  
These cell line-specific results classified the investigated Fn14+ iCCA lines as TWEAK-high 
responder (CC-SW-1 and SNU-1079) and TWEAK-low responder cell lines (CC-LP-1 and 
HuH-28) and provided evidence that TWEAK/Fn14 may play a role in the development of 
CCA by orchestrating the surrounding niche via localised NF-κB-mediated 
chemokine/cytokine secretion. 
 
3. TWEAK-induced CCA-derived factors regulate macrophage biology  
Tumour-associated macrophages (TAMs) play a critical role in providing pro-proliferative and 
pro-survival factors in CCA [7]. Since TWEAK induces the secretion of several pro-
inflammatory proteins in CCA cells, we investigated whether any of these TWEAK-induced, 
CCA-derived secreted proteins could affect macrophage phenotypes. To model the effect of 
TWEAK in CCA-induced patterning of macrophages in the CCA niche, we isolated human 
peripheral blood monocytes (Supplementary Figure 9A), differentiated these cells into 
macrophages (HMDMs) and subjected HMDMs to (a) PBS-supplemented basal medium 
11
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versus (b) TWEAK-supplemented basal medium, to assess the direct effects of TWEAK in 
HMDMs; or to (c) conditioned medium of 72 hours PBS-treated CCA cell lines versus (d) 
conditioned medium of 72 hours TWEAK-treated CCA cell lines, to measure the indirect 
effects of TWEAK in HMDMs via TWEAK-induced protein secretion in the CCA cell lines. 
HMDM differentiation was confirmed by 25F9 expression (Supplementary Figure 9B). 
Treatment with conditioned medium from TWEAK-stimulated TWEAK-high responder CCA 
lines (CC-SW-1 and SNU-1079) significantly increased cell surface expression of a TAM-
associated marker, CD206, in HMDMs. No significant difference was observed when 
conditioned medium from TWEAK-low responder CCA lines (CC-LP-1 and HuH-28 cells) 
was used (Figure 4A), suggesting that TWEAK-induced factors from some CCA cells can 
induce macrophage polarisation. We also assessed mRNA expression of several cytokines, 
chemokines, growth factors and receptors. HMDMs expressed 154- to 733-fold less Fn14 
mRNA than CCA/HCC cell lines (Supplementary Figure 9C) and did not modulate gene 
expression when treated with TWEAK alone (Figure 4B). Few genes were differentially 
regulated in HMDMs exposed to conditioned medium from the TWEAK-low responder CCA 
cells (MMP-2 in TWEAK-conditioned medium from CC-LP-1 cells, and TWEAK and CD163 
mRNA in TWEAK-conditioned medium from HuH-28 cells). However, expression of several 
key transcripts was induced in HMDMs treated with TWEAK-conditioned medium from CC-
SW-1 and SNU-1079 cells. IL-6 was upregulated in TWEAK-conditioned medium from both 
cell lines (82.6-fold and 105.2-fold), and TIMP-1 (4.5-fold and 4.3-fold). In CC-SW-1 
conditioned medium-patterned cells, we observed additional upregulation of CD80 (2.8-fold), 
M-CSF (6.2-fold) and TNF (3.9-fold). SNU-1079-patterned cells responded with additional 
upregulation of MCP-1 (4.0-fold) and vascular endothelial growth factor-alpha (VEGF-α; 4.5-
fold). We also assessed two surface markers associated with TAMs; triggering receptor 
expressed on myeloid cells 2 (TREM-2) and macrophage receptor with collagenous structure 
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(MARCO). All populations expressed TREM-2, and SNU-1079-patterned cells upregulated 
MARCO (18.1-fold; Figure 4B). 
 
4. MCP-1 is upregulated in CCA and affects macrophage accumulation in the tumour niche  
MCP-1 was the most abundant TWEAK-inducible protein produced by CCA cell lines (Figure 
2). In addition, MCP-1 was upregulated in macrophages by TWEAK-inducible factors 
produced by CCA cells (Figure 4). We therefore further investigated MCP-1 expression in 
CCA to link in vitro observations to human disease. In analysis of a scRNA-seq dataset 
(GSE125449; [26]), MCP-1 mRNA was expressed by CAFs, and subsets of tumour cells, HPCs 
and TAMs, while cognate receptor CCR2 was mainly expressed in TAMs and T cells 
(Supplementary Figure 10A). We observed increased MCP-1 immunostaining in archival 
human iCCA in tumour epithelia and widespread expression in stromal cells, compared to a 
subset of paired non-involved surrounding liver areas (Figure 5A), confirmed by pixel analysis 
(Figure 5B). 
 
Next, we assessed the co-regulation of the TWEAK/Fn14 pathway and MCP-1 expression in 
CCA epithelia. We stratified PanCK+ epithelial tumour cells into Fn14+ and Fn14- subsets, 
assessed the distribution of MCP-1+ cells in iCCA and further assessed these data with respect 
to tumour grade (Figure 5C). Importantly, MCP-1 expression was proportionally higher in 
Fn14+ versus Fn14- iCCA ducts in this cohort (Figure 5D; n=89). When stratified by tumour 
grade, this distribution was maintained in moderately differentiated grade 2 tumours 
(p<0.0001, n=32;) and poorly differentiated grade 3 tumours (p=0.0014, n=44; Figure 5D). 
This preferential distribution of MCP-1+ cells to Fn14+ tumour epithelia was also observed in 
our cohort of archival sections of iCCA patients and another commercially available CCA 
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tissue microarray (Supplementary Figure 10B), suggesting an active TWEAK/Fn14/MCP-1 
axis in a significant proportion of CCAs across three independent cohorts.  
 
We further assessed MCP-1 protein expression in two key components of the tumour niche; 
TAMs (CD68+) and CAFs (αSMA+). MCP-1 was expressed by 18.26% of CD68+ TAMs and 
18.52% of CAFs compared to 27.98% of malignant epithelia in this cohort of tumours (n=88-
90; Figure 5E). Having confirmed MCP-1 upregulation in clinical samples, we explored the 
temporal modulation and functional significance of MCP-1 upregulation during CCA 
development in rodent models. 
In rat CCA, small clusters of MCP-1+ cells were detected during early tumour development 
(Figure 6A). MCP-1 was expressed specifically in PanCK+ epithelia in tumour niches 
containing large areas of accumulated TAMs (CD68+; Figure 6B). MCP-1 mRNA also 
exhibited the bi-phasic expression observed for Fn14, increasing again after peak Fn14 
expression was observed during tumour formation (Figure 6C). MCP-1 was also expressed by 
CCA tumour cells in our previously described transgenic TAA CCA model [28] (Figure 6D), 
suggesting a critical, conserved role for MCP-1 during multi-species CCA development. 
 
To investigate the functional role of MCP-1 in recruiting macrophages to the CCA niche, we 
performed pharmacological blocking experiments using SNU-1079-generated human CCA 
cell xenografts (Figure 6E). Mice receiving multiple injections of anti-MCP-1 antibody formed 
significantly smaller tumours (Figure 6F), with 2.3-fold fewer intra-tumoral F4/80+ 
macrophages (Figure 6G), and 2.2-fold fewer CD206+ macrophages (Figure 6G), compared to 
control antibody-treated xenografts. We observed significantly more circulating MCP-1 
receptor (CCR2+) monocytes in anti-MCP-1-treated animals (Figure 6H). Although 
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subcutaneous xenografts do not recapitulate the entire liver microenvironment, they enable 
modelling of interactions between circulating immune cells and human CCA cells. Thus, these 
data provide a key functional context of the role of MCP-1 expression in CCA with in vivo 
evidence that recruitment of tumour-associated macrophages occurs via chemoattraction of 
CCR2+ monocytes.  
 
5. TWEAK signalling modulation affects tumour formation in vivo  
To characterise the effects of TWEAK on CCA tumour development, we used a previously 
described system of NICD and AKT overexpression in hepatocytes to induce CCA in six weeks 
(combination referred to as NICD/AKT, [30]). We compared tumours in this model to 
NICD/AKT tumours overexpressing TWEAK (combination referred to as 
NICD/AKT+TWEAK). The construct used to overexpress TWEAK also expressed red 
fluorescent protein (RFP), facilitating concurrent assessment of the localisation of TWEAK-
overexpressing cells (Supplementary Figure 11A). Macroscopic white, cyst-like lesions were 
observed on the surface of NICD/AKT livers (Figure 7A and Supplementary Figure 12A), 
analogous to previously published observation [30]. TWEAK overexpression produced 
striking alterations in the appearance of livers, with sizeable bile-containing cysts observed on 
the surface (Figure 7A, Supplementary Figure 12B). 
Microscopic histological characterisations of tumours using blinded assessment by an 
independent, specialist liver histopathologist revealed features that were consistent with this 
model [30]; tumours consisted of multifocal nodular lesions, often coalescing, precluding 
quantification of tumour number. Tumours were variably cystic and micropapillary epithelial 
neoplasms with cytological epithelial features in keeping with malignancy, with TWEAK 
overexpression increasing the cystic content of these tumours (Figure 7B, Supplementary 
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Figure 11B). Formal observer-independent quantification of tumour elements showed that 
TWEAK overexpression increased the total tumour area and cystic percentage of tumours 
(Figure 7C). The tumour epithelial area was not altered by TWEAK overexpression (Figure 
7C). Accordingly, CK19+ epithelium with active, nuclear localisation of phosphorylated NF-
κB p65 in either bile duct or CCA tissue was similar in both conditions (Figure 7D), and most 
CCA cells were proliferating (Ki67+; Figure 7E), presumably as a result of AKT 
overexpression [30]. We did not find an association between the tumour cystic grade and the 
proportion of Fn14+ cells in CCA cells or CAFs in patient tissues (Supplementary Figure 13). 
 
Complementing our xenograft results, we observed increases in innate immune cells with 
TWEAK overexpression, including CD11b+ monocyte/neutrophils that clustered within the 
tumour niche in cystic tumour areas (Supplementary Figure 11C), and a 2-fold increase in 
CD206+ macrophage numbers (Supplementary Figure 11C). In addition, GM-CSF was 
upregulated in liver and plasma with TWEAK overexpression (Supplementary Figure 11D).  
 
TWEAK overexpression also significantly affected the CAF subcompartment of the CCA 
niche, previously shown to express Fn14+ in patient iCCAs (Figure 1). We detected a 1.32-fold 
increase in the αSMA+ CAF area and the Picrosirius Red-positive collagen area in 
NICD/AKT+TWEAK tumours (Figure 7F). TWEAK activation of canonical NF-κB 
signalling, demonstrated by an increased proportion of CAFs expressing nuclear phospho-p65 
(Figure 7G), has previously been shown to drive hepatic stellate cell proliferation in chronic 
liver injury [23]. We observed a 1.53-fold increase in proliferating Ki67+/αSMA+ CAFs in 
TWEAK-overexpressing CCAs (Figure 7G). 
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Having established novel roles of TWEAK in inflammatory and fibrogenic niche development 
in CCA, critical components of a tumour-permissive environment [31], we assessed TAA-
mediated chronic liver disease in homozygous Fn14 knockout mice compared to wildtype 
Fn14-expressing littermate controls (Supplementary Figure 14A). Following six months of 
TAA injury, significant macroscopic tumour formation was observed in Fn14 wildtype mice 
(12/12 animals with one or multiple tumours; 2, <2 mm; 9, 2-5 mm, 1, >5 mm diameter), while 
1/9 Fn14 knockout mice displayed an early tumour of less than 2 mm in diameter 
(Supplementary Figure 14B). Concomitant with tumour inhibition in Fn14 knockout mice, we 
observed a reduction in PanCK+ cells as well as F4/80+ and CD206+ macrophages 
(Supplementary Figure 14C, 14D). MCP-1, GM-CSF, IL-6 and KC/Gro remained at steady-
state levels in 6-month TAA-treated mice (Supplementary Figure 14E). These data support our 
hypothesis that TWEAK/Fn14 signalling plays a pivotal role in niche establishment during 
chronic liver injury, capable of supporting hepatic tumour development.  
 
DISCUSSION 
During chronic liver injury, macrophage-produced TWEAK drives proliferation of Fn14+ 
cholangiocytes to initiate hepatic regeneration [21, 22, 32] and αSMA+ myofibroblasts, 
affecting extracellular matrix deposition in damaged liver areas by regulating their cell 
numbers [23, 24]. Macrophages comprise the majority inflammatory cell infiltrate in the CCA 
stroma [15-17, 19], providing key signals such as Wnt ligands to induce growth and apoptosis 
resistance [6, 7], and cytokines including IL-6, TNF and TGF-β1 to promote metastatic 
progression [15, 17]. We hypothesised that TWEAK/Fn14-induced downstream signalling 
represents a significant pathway, supporting CCA growth and maintenance.  
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Through corroboration of transcriptomic data from multiple independent CCA patient cohorts 
and characterisation of patient samples, we demonstrated upregulation of Fn14 in CCA, on 
tumour epithelial cells and CAFs, compared to non-involved liver tissue. Significantly, a subset 
of TWEAK-expressing TAMs localised within the CCA niche, suggesting interplay between 
ligand-expressing niche and receptor-expressing tumour/niche via TWEAK/Fn14, potentiating 
therapeutic targeting. We demonstrated that TWEAK/Fn14 pathway elements are 
progressively upregulated in rodent CCA tissues. Previous studies reported proliferation of 
biliary epithelial, and HCC cells, in response to TWEAK [21, 22, 25, 32]. We explored the 
effects of TWEAK in CCA lines, and found TWEAK elicited NF-κB signalling modulations 
in all investigated CCA cell lines, but not HepG2 HCC cells. However, this signal led to cell 
line-specific cellular responses, suggesting more complex functions for TWEAK/Fn14 
signalling in CCA. 
In chronic injury, NF-κB controls the expression of a multitude of chemokines and growth 
factors that regulate liver inflammation and repair, including MCP-1 [33], while aberrant 
expression of NF-κB pathway components results in spontaneous liver fibrosis and eventual 
HCC in genetic mouse models [34-36]. Although TWEAK-responsive NF-κB pathway 
activation was seen in all CCA cell lines we assessed, we did not observe consistent 
proliferative effects, as reported in other liver cell types [21, 22, 25]. In response to TWEAK 
stimulation, CCA cells secreted proinflammatory chemokines and growth factors, suggesting 
TWEAK can regulate CCA niche development. We further explored the functional role of 
MCP-1, which drives inflammatory macrophage recruitment to sites of liver injury via its 
receptor CCR2 [37, 38]. Disrupting MCP-1/CCR2 has proven effective in inhibiting TAM 
accumulation and tumour development in preclinical HCC models [39, 40]. We observed in 
vitro TWEAK-inducible MCP-1 expression and detected MCP-1 in tumour cells in multi-
species CCA. MCP-1 inhibition reduced SNU-1079 xenograft size, with accumulation of 
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CCR2+ monocytes in peripheral blood and decreased TAMs, providing evidence for an MCP-
1-mediated macrophage recruitment to the tumour niche by CCA cells. Further support for this 
axis having a functional role is provided by our data from TAA-treated Fn14 knockout mice, 
which displayed significantly reduced macrophages and drastically inhibited or delayed 
tumorigenesis.  
 
We also report a novel function of TWEAK in the liver in driving the secretion of factors from 
CCA cells that alter macrophage phenotype. CCA cells actively educated macrophages towards 
a TAM-like phenotype, expressing a mixture of classically activated and alternative activation 
markers, as well as upregulating molecules involved in matrix remodelling [18]. In TWEAK-
high responsive CCA cell lines (SNU-1079 and CC-SW-1), we observed an increased ability 
to pattern macrophages towards a TAM-like ‘M2-skewed’ phenotype with CD206 and pro-
inflammatory gene expression including IL-6, TNF and MCP-1, reminiscent of TAMs 
observed in CCA [7, 17, 19]. Additionally, CCA-patterned macrophages also upregulated the 
scavenger receptor MARCO, a marker of immunosuppressive TAMs in many tumour types 
[41]. Data from progressive CCA in rats demonstrated that Fn14 and MCP-1 upregulation is 
co-regulated early in CCA development. Furthermore, TWEAK overexpression in CCA 
promoted a dramatic tumour phenotype alteration by inducing expansion of collagen-
producing CAFs, which we show to express Fn14 in a significant proportion of patient iCCAs. 
By driving inflammatory chemokine production, altering macrophage phenotype via crosstalk 
with CCA epithelia and promoting fibroblastic growth within the CCA microenvironment via 
a direct action of TWEAK on CAF proliferation, upregulation of TWEAK/Fn14 signalling 
appears to be an early driver, promoting the development of a niche that supports tumour 
growth. Our data using genetic knockout or antibody inhibition of TWEAK downstream events 
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highlight the potential for clinically relevant therapeutic targeting. A humanised antibody 
against TWEAK, RG7212, is currently being investigated for its efficacy in treating late stage 
Fn14+ solid tumours in malignancies including colorectal cancer, melanoma and a cohort of 
three CCA patients, with antibody treatment well-tolerated. Noteworthy, one of the desired 
actions of antibody treatment is to reduce serum MCP-1 levels [42, 43].  
 
In addition to affecting the CAF and TAM niche compartments, we also report TWEAK-
induced secretion of molecules involved in blood vessel development and angiogenesis from 
CCA cell lines. Macrophages patterned by TWEAK-inducible factors from SNU-1079 cells 
also upregulated VEGF-α mRNA. Significantly, VEGF-A and VEGF-C from CAFs are 
important mediators of lymphangiogenesis in CCA [44], which is correlated with poor patient 
outcomes [45]. We also observed some vascular Fn14 expression in rat and human CCA. 
TWEAK can stimulate endothelial cell proliferation, following Fn14 upregulation in response 
to VEGF-A and FGF-2 [46]. Given our in vitro proteomic and macrophage patterning results, 
combined with observation in patient samples, there is future scope to ascertain the role of 
TWEAK/Fn14 signalling in metastatic progression by acting directly on endothelium, and 
indirectly via secretion of proteins from tumour cells, tumour-conditioned TAMs and CAFs, 
which promote tumour progression via pathways such as VEGF-A and VEGF-C.  
 
Our study provides a detailed and novel mechanistic framework of how the TWEAK/Fn14 
pathway is involved in building a tumour-permissive niche, acting on TAMs and CAFs in 
CCA, which both drive chemotherapy resistance [47]. Given the significant proportion of CCA 
patients exhibiting aberrant upregulation of Fn14, targeting TWEAK/Fn14, may provide 
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avenues to interrupt epithelial-stromal crosstalk to create novel therapeutics for a cancer where 
effective treatments are urgently required.  
 
Abbreviations: AKT- Protein Kinase B; CAF-Cancer-Associated Fibroblast; CCA- 
Cholangiocarcinoma; CCR2- C-C Chemokine Receptor type 2; CK- Cytokeratin; CX3CL1- 
(C-X3-C motif) Ligand 1;ERK- Extracellular Signal-Related Kinase; Fn14- Fibroblast 
Growth Factor-Inducible; GM-CSF- Granulocyte Macrophage Colony Stimulating Factor; 
HCC- Hepatocellular Carcinoma; HMDM- Human Monocyte-Derived Macrophage; HPC- 
Hepatic Progenitor Cell; IL- Interleukin; MARCO- Macrophage Receptor with Collagenous 
Structure; MCP-1- Monocyte Chemoattractant Protein 1; M-CSF- Macrophage Colony-
Stimulating Factor; MMP- Matrix Metalloprotease; NF- Nuclear Factor; NICD- Notch 
Intracellular Domain; SDF- Stromal-Derived Factor; TAA- Thioacetamide; TAM- Tumour-
Associated Macrophage; TCGA- The Cancer Genome Atlas; TIMP- Tissue Inhibitors of 
Metalloproteases; TREM-2- Triggering Receptor Expressed on Myeloid Cells-2; TWEAK- 
TNF-Like Weak Inducer of Apoptosis; αSMA- α-Smooth Muscle Actin  
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FIGURE LEGENDS 
Figure 1. TWEAK/Fn14 expression in cholangiocarcinoma (CCA). (A) Fn14 
immunohistochemistry in archival paraffin sections of patient-matched intrahepatic CCA 
(iCCA) versus non-involved areas of surrounding liver (SL; n=42 iCCA vs. n=26 SL) (B) 
Quantification of Fn14 immunostaining (Mann-Whitney U test). (C) Single cell RNA-
sequencing data of iCCA (GSE125449; n=5 per cohort). Cell types: B-cells, cancer-associated 
fibroblasts (CAF), hepatic progenitor cells (HPC), malignant cells (Malig.), tumour-associated 
macrophages (TAM), T-cells, tumour endothelial cells (TEC), undefined. (D) Staining of Fn14 
(red) in tumour cells (PanCK; white) and CAFs (αSMA; green) in an iCCA tissue microarray. 
Nuclei are stained with DAPI (blue). Proportion of Fn14+ tumour cells (n=84) and CAFs (n=74) 
by tumour grade (Kruskal-Wallis test with Dunn’s multiple comparison test). Data are mean ± 
SEM. *p<0.05,**p<0.01. Scale bars represent 100 µm. 
 
Figure 2. TWEAK/Fn14 upregulation in rodent cholangiocarcinoma (CCA). (A) 
Schematic of thioacetamide (TAA) treatment of rats to induce CCA. (B) Dual 
immunofluorescence reveals Fn14+ (green) tumour epithelia (PanCK+; red). (C) mRNA 
expression of Fn14 and TWEAK in a time course of TAA treatment in rats (n=3 to 11; Kruskal-
Wallis with Dunn’s post-test) (D) Schematic of TAA treatment of Krt19-CreERTR26-
eYFPp53flox/het/wt mice to induce CCA. (E) mRNA expression of Fn14 and TWEAK in Krt19-
CreERTR26-eYFPp53Fl/WT or Krt19-CreERTR26-eYFPp53WT/WT (p53wt/het; no CCA, n=9) vs. 
Krt19-CreERTR26-eYFPp53flox/flox (p53f/f; CCA, n=6; Mann-Whitney U test). (F) Protein 
expression of Fn14 in mouse p53wt/het vs. p53flox/flox mice (n=7 each; unpaired t-test). Data are 
mean ± SEM. *p<0.05,**p<0.01.***p<0.001. Scale bars represent 50 µm. 
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Figure 3. TWEAK signalling drives NF-κB pathway activation and protein production. 
(A) TWEAK-dependent modulation of NF-κB pathway proteins in cholangiocarcinoma (CCA) 
cells and quantification of NF-κB protein expression 2h-post rhTWEAK exposure. (B) 
Localisation of NF-κB p65 subunit in CCA cell lines with TWEAK treatment. (C) MTT assay 
in CCA lines following 72 h treatment with increasing dose of rhTWEAK. (D) TWEAK-
dependent mRNA expression in CCA lines following 6 h rhTWEAK treatment. (E) Protein 
immunoassay of secreted proteins from CCA lines treated with PBS or rhTWEAK. Data are 
mean ± SEM. unpaired t-test (n=3) or one-way ANOVA with Dunnett’s post-test (MTT assay; 
n=6); *p<0.05,**p<0.01,***p<0.001. Scale bars represent 50 µm. 
 
Figure 4. Cholangiocarcinoma (CCA)-derived TWEAK-inducible factors drive 
macrophage patterning. (A) Cell surface CD206 expression (median fluorescence intensity; 
MFI) in HMDMs treated with conditioned medium (CM) from PBS- or TWEAK-treated CCA 
cells (One-way ANOVA with Tukey’s post-test; n=3). (B) mRNA expression in HMDMs 
treated with conditioned medium from PBS- or TWEAK-treated CCA cells (n=3). Fold 
changes expression was calculated compared to control DMEM with PBS (DMEM+PBS) and 
analysed using one-way ANOVA with Dunnett’s multiple comparison test. 
*p<0.05,**p<0.01,***p<0.001. Data are mean ± SEM. 
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Figure 5. MCP-1 expression in cholangiocarcinoma (CCA). (A) MCP-1 
immunohistochemistry in archival paraffin sections of patient-matched intrahepatic CCA 
(iCCA) versus adjacent non-involved surrounding liver areas (SL). (B) Digital pixel analysis 
of sections (n=42 iCCA vs. n=26 SL; Mann-Whitney U test). (C) Staining of tumour liver tissue 
from an iCCA tissue microarray (n=89) with PanCK (white), Fn14 (red), MCP-1 (green). 
Nuclei are stained with DAPI (blue). (D) Analysis of total distribution of MCP-1+ cells in Fn14- 
and Fn14+ subsets of PanCK+ tumour cells in individual CCA tissues or stratified with respect 
to tumour grade (Wilcoxon matched-pairs signed rank test). (E) Assessment of distribution in 
MCP-1+ cells (red) in CD68+ macrophages (green) and αSMA+ CAFs (white). Nuclei are 
stained with DAPI (blue). Data are mean ± SEM. *p<0.05,**p<0.01,****p<0.0001. Scale bars 
represent 100 µm. 
 
Figure 6. MCP-1 in rodent cholangiocarcinoma (CCA). (A) MCP-1 immunohistochemistry 
(IHC) in liver from rats administered TAA for 10 weeks (injured, pre-malignant) up to 26 
weeks. (B) Triple immunofluorescence reveals MCP-1+ tumour epithelia (PanCK+) with 
interspersed macrophage infiltration (CD68) in rat CCA. (C) mRNA expression of MCP-1 in 
a time course of TAA treatment in rats (n=3-11 per timepoint; Kruskal-Wallis test with Dunn’s 
post-test). (D) Triple immunofluorescence reveals MCP-1+ tumour epithelia (PanCK+) with 
interspersed macrophage infiltration (F4/80+) in Krt19-CreERTR26-eYFPp53Fl/Fl mice 
administered TAA for 26 weeks to induce CCA. (E) Schematic of xenograft experiments. (F) 
SNU-1079 xenografts in CD-1 nude mice treated with control or anti-MCP-1 antibody (n=8 
per group; unpaired t-test). (G) Macrophage marker (F4/80, CD206) staining of SNU-1079 
xenografts (n=7 isotype vs. n=6 treated with anti-MCP-1; Mann-Whitney U test). (H) Analysis 
of peripheral blood monocytes of xenografted CD-1 nude mice (n=7 isotype vs. n=8 anti-MCP-
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1 treated; unpaired t-test). Data are mean ± SEM. *p<0.05,**p<0.01,***p<0.001. Scale bars 
represent 50 µm. 
 
 
Figure 7. TWEAK drives cancer-associated fibroblast (CAF) proliferation 
in cholangiocarcinoma (CCA). CCA was induced in mice with overexpression of 
Notch Intra-Cellular Domain and AKT (NICD/AKT) w i t h  effects of TWEAK 
overexpression (NICD/AKT+TWEAK) assessed. (A) Gross morphology of livers. (B) 
Haematoxylin and eosin- stained liver sections. (C) Tumour area ( Mann-Whitney U test) 
and cystic and tumour epithelial area quantification. (D) S taining of biliary tissue (CK19) 
and phosphorylated NF-kB p65 (p-p65) in normal and CCA areas. (E) Staining of biliary 
tissue and proliferation marker (Ki67). (F) Quantification of CAF (αSMA+) area and 
collagen deposition ( Picrosirius Red (PSR) staining). (G) Staining of CAF (αSMA) and p-
p65 or proliferation marker (Ki67). Data are mean ± SEM. 
*p<0.05,***p<0.001,****p<0.0001. Unpaired t-test unless otherwise stated. Scale bars 
represent 100 µm. 
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Highlights:  
1. Fn14 is upregulated in on tumour cells and cancer associated fibroblasts, and 
TWEAK is expressed by tumour associated macrophages in human CCA. 
TWEAK/Fn14 are progressively upregulated during rodent tumour development, with 
Fn14 upregulated in dysplastic biliary lesions in pre-neoplastic liver in rats. 
2. TWEAK/Fn14 signalling induces tumour associated macrophage accumulation via 
TWEAK-inducible MCP-1 chemotaxis which can be blocked in vivo. 
3. TWEAK-inducible factors from tumour cells pattern macrophages to a TAM-like 
phenotype, upregulating CD206, and the expression of MCP-1, IL-6, TNF, VEGF-α 
and MARCO 
4. TWEAK overexpression in experimental tumour formation drives CAF proliferation, 
collagen deposition and increases macrophages in mice, whilst tumour formation is 
reduced with genetic deletion of Fn14. 
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